Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Effects of Bisoprolol and Verapamil in Patients with Non-Obstructive Hypertrophic Cardiomyopathy

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of two medications, Bisoprolol and Verapamil, in patients with a heart condition known as non-obstructive hypertrophic cardiomyopathy. This condition involves the thickening of the heart muscle, which can lead to symptoms like shortness of breath, chest pain, and irregular heartbeats. The purpose of the study is to see how these medications can help reduce symptoms and complications related to this heart condition.

Participants in the study will receive either Bisoprolol, Verapamil, or a placebo. Bisoprolol is a medication that helps lower blood pressure and reduce heart rate, while Verapamil is used to relax the heart muscles and improve blood flow. The study will last for a period of three months, during which the effects of these medications on heart function and symptoms will be monitored. The study aims to measure changes in the heart's ability to pump blood, the size of the heart chambers, and the occurrence of irregular heartbeats.

Throughout the study, participants will undergo various tests to assess their heart health, including measurements of oxygen consumption and heart volume. The study will also look at how these medications affect the quality of life and symptom severity in patients. By the end of the study, researchers hope to better understand how Bisoprolol and Verapamil can be used to manage symptoms in people with non-obstructive hypertrophic cardiomyopathy.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on specific criteria such as age and medical history related to non-obstructive hypertrophic cardiomyopathy.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to establish baseline measurements. This includes evaluating maximal oxygen consumption (VO2 max), left ventricular end-diastolic volume, and the incidence of non-sustained ventricular tachycardia.

  3. Step 3

    Medication administration

    Participants receive either Bisoprolol or Verapamil, or a placebo. These medications are administered orally. The dosage and frequency are determined by the study protocol and adjusted based on individual tolerance.

  4. Step 4

    Ongoing monitoring

    Throughout the trial, regular monitoring is conducted to assess the effects of the medication. This includes measuring changes in VO2 max, left ventricular volume, and the occurrence of arrhythmias.

    Additional assessments may include questionnaires and various tests such as echocardiography and ambulatory ECG monitoring.

  5. Step 5

    Final evaluation

    At the end of the trial, a final evaluation is performed to compare the initial and final measurements. This helps determine the effectiveness of the treatment in reducing symptoms and complications associated with non-obstructive hypertrophic cardiomyopathy.

Who can join the trial?

8 criteria

  • Must be **18 years or older**.
  • Have a **heart wall thickness** of **15 mm or more** that is not caused by high blood pressure, valve diseases, or storage diseases.
  • Meet at least one of the following conditions:
    • Experience symptoms that are classified as **New York Heart Association (NYHA) class II or higher**. This means having some limitation in physical activity due to heart symptoms.
    • Have a history of NYHA class II or higher before starting treatment with **beta-blockers (BB)** or **calcium channel blockers (CCB)**. These are types of medications used to treat heart conditions.
    • Have a **Pro-BNP** level greater than **300 ng/l** or a **BNP** level greater than **100 ng/l**. These are blood tests that measure substances released by the heart when it is under stress.
    • Have experienced **non-sustained ventricular tachycardia (VT)**, which is a fast heart rhythm, with a rate of more than **120 beats per minute** and lasting for at least **3 cycles**, documented within the last **2 years**.
    • Both **male and female** participants are eligible.
    • Participants should not belong to a **vulnerable population**.

Who cannot join the trial?

5 criteria

  • Patients with other types of heart conditions that are not related to non-obstructive hypertrophic cardiomyopathy cannot participate. This is a specific heart condition where the heart muscle becomes thick but does not block blood flow.
  • Individuals who are not within the specified age range for the study are excluded. The study is only for certain age groups.
  • Participants who are not able to safely take the study medications, such as Bisoprolol and Verapamil, are not eligible. These are medications used to manage heart conditions.
  • People with certain medical conditions that might interfere with the study or make it unsafe for them to participate are excluded.
  • Individuals who are part of a vulnerable population, meaning they might need special protection or care, are not included in the study.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Bisoprolol

    is a medication used in this trial to help manage symptoms in patients with non-obstructive hypertrophic cardiomyopathy. It works by slowing down the heart rate and reducing the heart's workload, which can help improve the heart's efficiency and reduce symptoms like shortness of breath and chest pain.

  • Verapamil

    is another medication involved in the trial. It is used to help control heart rate and rhythm. Verapamil can help relax the heart muscles and blood vessels, which may improve blood flow and reduce the risk of arrhythmic complications in patients with non-obstructive hypertrophic cardiomyopathy.

What is already known about the treatment

  • Bisoprolol

    Bisoprolol is administered orally in tablet form. It is currently used in medicine to manage heart conditions, particularly high blood pressure and heart failure. In the context of non-obstructive hypertrophic cardiomyopathy, it helps reduce symptoms and arrhythmic complications. Bisoprolol works by blocking beta-adrenergic receptors, which decreases heart rate and the force of heart muscle contraction, leading to reduced oxygen demand by the heart. It is classified as a beta-blocker.

  • Verapamil

    Verapamil is available in oral tablet form and can also be administered intravenously. It is widely recognized in medical literature for treating high blood pressure, angina, and certain heart rhythm disorders. For non-obstructive hypertrophic cardiomyopathy, Verapamil aims to alleviate symptoms and prevent arrhythmias. It functions by inhibiting calcium channels in the heart and blood vessels, which relaxes the heart muscle and dilates blood vessels, improving blood flow and reducing heart workload. Verapamil is classified as a calcium channel blocker.

Investigated diseases

Non-obstructive hypertrophic cardiomyopathy – This is a condition where the heart muscle becomes abnormally thick without any blockage in the blood flow. The thickened heart muscle can make it harder for the heart to pump blood efficiently. Over time, this can lead to symptoms such as shortness of breath, chest pain, and palpitations. The disease can also cause arrhythmias, which are irregular heartbeats. It is a genetic condition, often inherited, and can vary greatly in severity among individuals. The progression of the disease can lead to changes in heart function and structure, affecting overall cardiovascular health.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-515346-17-00Estimated enrolment140 patientsSponsorRegion Midtjylland

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.